Efficacy of Humanized Exposures of Cefiderocol (S-649266) against a Diverse Population of Gram-Negative Bacteria in a Murine Thigh Infection Model
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Cefiderocol (S-649266) is a novel siderophore cephalosporin with potent in vitro activity against clinically encountered multidrug-resistant (MDR) Gram-negative isolates; however, its spectrum of antibacterial activity against these difficult-to-treat isolates remains to be fully explored in vivo . Here, we evaluated the efficacy of cefiderocol humanized exposures in a neutropenic murine thigh model to support a suitable MIC breakpoint. Furthermore, we compared cefiderocol's efficacy with humanized exposures of meropenem and cefepime against a subset of these phenotypically diverse isolates. Ninety-five Gram-negative isolates were studied. Efficacy was determined as the change in log 10 CFU at 24 h compared with 0-h controls. Bacterial stasis or ≥1 log reduction in 67 isolates with MICs of ≤4 μg/ml was noted in 77, 88, and 85% of Enterobacteriaceae , Acinetobacter baumannii , and Pseudomonas aeruginosa , respectively. For isolates with MICs of ≥8 μg/ml, bacterial stasis or ≥1 log 10 reduction was observed in only 2 of 28 (8 Enterobacteriaceae , 19 A. baumannii , and 1 P. aeruginosa ) strains. Against highly resistant meropenem and cefepime organisms, cefiderocol maintained its in vivo efficacy. Overall, humanized exposures of cefiderocol produced similar reductions in bacterial density for organisms with MICs of ≤4 μg/ml, whereas isolates with MICs of ≥8 μg/ml generally displayed bacterial growth in the presence of the compound. Data derived in the current study will assist with the delineation of MIC susceptibility breakpoints for cefiderocol against these important nosocomial Gram-negative pathogens; however, additional clinical data are required to substantiate these observations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ito, A., Nishikawa, T., Matsumoto, S., Yoshizawa, H., Sato, T., Nakamura, R., Tsuji, M., & Yamano, Y. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01405-16 · Cited by 352 · cited 1×
“This unique structural characteristic allows the agent to form a chelating complex with free iron, which is then actively transported across the outer membrane into the cell via specialized iron transporters (4).”
BackgroundSelf-citation
Cited by
Tamma, P. D., Heil, E. L., Justo, J. A., Mathers, A. J., Satlin, M. J., & Bonomo, R. A. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae403 · Cited by 1,191
Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections
Doi, Y. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz830 · Cited by 652
Tamma, P. D., Aitken, S. L., Bonomo, R. A., Mathers, A. J., van Duin, D., & Clancy, C. J. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciab1013 · Cited by 519
Zhanel, G. G., Golden, A. R., Zelenitsky, S., Wiebe, K., Lawrence, C. K., Adam, H. J., Idowu, T., Domalaon, R., Schweizer, F., Zhanel, M. A., et al. (2019) · Drugs · doi:10.1007/s40265-019-1055-2 · Cited by 446
New Treatment Options against Carbapenem-Resistant Acinetobacter baumannii Infections
Isler, B., Doi, Y., Bonomo, R. A., & Paterson, D. L. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01110-18 · Cited by 293
Metadata
- Authors
- Monogue, M. L., Tsuji, M., Yamano, Y., Echols, R., & Nicolau, D. P.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2017-11
- Volume
- 61
- Issue
- 11
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2749795132
- Cited by
- 101
- References
- 1
- FWCI
- 3.88
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.